– Inteview with Kevin Verstrepen, Ph.D., Group Leader, Laboratory of Systems Biology, Flanders Institute for Biotechnology, and Associate Professor, Biological Engineering, Catholic University of Leuven

Previous articleChoosing a Clinical Trial Disclosure System
Next articleGenzyme Plant Shutdown Could Mean up to $300M in Lost Sales